Determination of serum hepatitis C virus (HCV) core protein using a novel approach for quantitative evaluation of HCV viraemia in anti-HCV-positive patients

Liver

Volumn 19, Issue 5, 1999, Pages 375-380

  Komatsu, Fumio ^a   Takasaki, Kanae ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Anti HCV; HCV core protein; HCV RNA; Interferon therapy; RT PCR

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CORE PROTEIN; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGED; AGGLUTINATION TEST; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PROTEIN DETERMINATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGGLUTINATION TESTS; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL CORE PROTEINS; VIREMIA;

EID: 0032867139     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00065.x     Document Type: Article

References (16)

1. GONZALEZ A, ESTEBAN J I, MADOZ P, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial. Hepatology 1995; 22: 439-45.
2. HENRARD DR, BERTHILLON P, SCHEFFEL JW, et al. Lack of evidence of hepatitis C infection in 290 blood component recipients, demonstrated by several single-antigen research immunoassays. Transfusion 1998; 38: 194-8.
3. SCHREIBER G B, BUSCH M P, KLEINMAN S H, KORELITZ J J. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334: 1685-90.
4. DIKE A E, CHRISTIE J M L, KURTS J B, TEO C-G. Hepatitis C in blood transfusion recipients identified at the Oxford Blood Centre in the national HCV look-back programme. Transfus Med 1998; 8: 87-95.
5. OKAMOTO H, OKADA S, SUGIYAMA Y, et al. Detection of hepatitis C virus RNA by two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990; 60: 215-22.
6. KATO N, YOKOSUKA O, HOSODA K, et al. Quantification of hepatitis C virus by competitive reverse transription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993; 18: 16-20.
7. ROTH W K, LEE J-H, RUSTER B, ZEUZEM S. Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996; 34: 261-4.
8. LAU J Y N, DAVIS G L, KNIFFEN J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
9. TANAKA E, KIYOSAWA K, MATSUMOTO A, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alpha. Hepatology 1996; 23: 1330-3.
10. KASHIWAKUMA T, HASEGAWA A, KAJITA T, et al. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Methods 1996; 190: 79-89.
11. TANAKA T, TSUKIYAMA-KOHARA K. YAMAGUCHI K, et al. Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 1994; 19: 1347-53.
12. SIMMONDS P. ALBERTI A, ALTER H J, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
13. TANAKA T, LAU J Y N, MIZOKAMI M, et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viraemia. J Hepatol 1995; 23: 742-5.
14. WATANABE J, MATSUMOTO C, FUJIMURA K, et al. Predictive value of screening tests for persistent hepatitis C virus infection evidenced by viraemia. Vox Sang 1993; 65: 199-203.
15. KOHARA M, TANAKA T, TSUKIYAMA-KOHARA K, et al. Hepatitis C virus genotypes 1 and 2 respond to interferon-αwith different virologic kinetics. J Infect Dis 1995; 172: 934-8.
16. CHAYAMA K, TSUBOTA A, ARASE Y. et al. Genotype, slow decrease in virus titer during Interferon treatment and high degree of sequence variability of hypervariable region are indicative of poor response to interferon treatment in patients with chronic hepatitis type C. J Hepatol 1995; 23: 648-53.